Country

China

Publisher

Chinese Medical Association Publishing House and Wiley

ElectronicLinks

Editor-in-chief

Jun Wang

E-mail

cdtm@cmaph.org

Abbreviation

Chronic Dis Transl Med

Vernacular Journal Title

慢性疾病与转化医学（英文）

ISSN

2095-882X

EISSN

2589-0514

Year Approved

2025

Current Indexing Status

Currently Indexed

Start Year

2015

Description

Chronic Diseases and Translational Medicine (CDTM) (CN 10-1249/R) is a peer-reviewed, open-access quarterly journal established in 2015. It is jointly published by the Chinese Medical Association Publishing House and Wiley. The journal operates under the administration of the China Association for Science and Technology (CAST). This journal is focused on chronic diseases including oncological, cardiovascular, respiratory, endocrine, renal and immune diseases, and related translational medicine for these diseases. We strive to build an international platform to enable local and international researchers to publish articles on the latest research findings and cutting-edge advances in chronic diseases and translational medicine, and push the boundary of science through academic exchanges. The academic quality of CDTM has been widely recognized by authoritative international and local databases. It has been indexed in Scopus, PubMed, PubMed Central, Embase, CAS, DOAJ, Chinese Science and Technology Paper and Citation Database (CSTPCD), Chinese Science Citation Database (CSCD) core database, COAJ, Google Scholar, and Ulrich’s Periodicals Directory. CDTM achieved a Scopus CiteScore of 4.6 in 2024 and has ranked among the top 20% of journals worldwide in the General Medicine category for four consecutive years. What’s more, this journal has been consecutively honored as an " China's Outstanding Academic Journal With International Influence " for several years and was included in the World Journal Citation Index (WJCI) Report. In December 2024, it was selected for the Chinese Science and Technology Journal Excellence Action. CDTM is grounded in a commitment to open, rigorous, and ethical scholarship. As a fully open-access journal operating under CC BY, CC BY-NC, or CC BY-NC-ND licenses, CDTM removes subscription barriers to ensure that researchers, clinicians, and policy-makers worldwide can freely access and reuse its content. Every submission undergoes a double-anonymous peer review overseen by an international editorial board, balancing scientific rigor with clinical relevance. By maintaining an average submission-to-publication timeframe of roughly 14 weeks, the journal strikes a careful balance between thorough evaluation and the rapid dissemination of new findings. In addressing the global challenge of chronic diseases—which now account for more than 70 percent of all deaths worldwide—CDTM plays a vital role in bridging gaps between molecular discoveries, clinical practice, public health policy, and patient outcomes. Its open-access model democratizes knowledge, making state-of-the-art research available to practitioners and scientists in low- and middle-income settings who might otherwise face paywalls. Through broad international indexing and a multidisciplinary scope, CDTM fosters cross-border collaboration, accelerates innovation in prevention, diagnosis, and treatment, and informs evidence-based guidelines and health strategies that can be adapted to diverse healthcare systems around the world.